What the FDA labels say about taking them together
Budesonide and erythromycin
Budesonide's FDA label (Eohilia) of February 3, 2025 names erythromycin in its drug interactions section; the erythromycin labels PlainMeds reads (4) do not name budesonide. The budesonide label: “Inhibitors of CYP3A4 can increase systemic budesonide concentrations.”
Check it at the source: the budesonide FDA label on DailyMed (effective October 11, 2019, AstraZeneca Pharmaceuticals LP); the erythromycin FDA label on DailyMed (effective August 1, 2024, Teva Pharmaceuticals USA, Inc.).
What does the budesonide label say about erythromycin?
Eohilia label (TAKEDA PHARMACEUTICALS AMERICA, INC., February 3, 2025), drug interactionsConcomitant use of budesonide with CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, erythromycin, cyclosporine, grapefruit juice) can increase systemic budesonide concentrations [see Clinical Pharmacology (12.3) ].
Tarpeyo label (Calliditas Therapeutics AB, January 21, 2026), drug interactionsAvoid use with potent CYP3A4 inhibitors; e.g. ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, erythromycin, and cyclosporine [see Clinical Pharmacology ( 12.3 )].
Budesonide label (Padagis US LLC, June 5, 2024), drug interactionsInhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, erythromycin, and cyclosporine) can increase systemic budesonide concentrations [see Clinical Pharmacology (12.3)].
Source: FDA drug label (Eohilia, NDA213976), TAKEDA PHARMACEUTICALS AMERICA, INC., effective February 3, 2025 (SPL set 56f2023a-69b2-4470-b4ad-af7ec1be527a), via openFDA
Source: FDA drug label (Tarpeyo, NDA215935), Calliditas Therapeutics AB, effective January 21, 2026 (SPL set 938cada4-d6bf-4252-836f-dd40f9eadb4d), via openFDA
Source: FDA drug label (Budesonide, NDA021324), Padagis US LLC, effective June 5, 2024 (SPL set 3a18d5a7-04c5-4137-8155-70a8adc0a48b), via openFDA
Source: FDA drug label (PULMICORT RESPULES), AstraZeneca Pharmaceuticals LP, effective October 11, 2019 (SPL set 33cd9834-76df-4f26-3fa2-aab6b9eee8f2), via openFDA; the full label on DailyMed
What does the erythromycin label say about budesonide?
Erythromycin's label (effective August 1, 2024) and its 3 other brand-application labels do not name budesonide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Erythromycin), Teva Pharmaceuticals USA, Inc., effective August 1, 2024 (SPL set 75a0bd5a-d09f-483b-bfd8-f8343b149eb2), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Budesonide | Erythromycin | |
|---|---|---|
| Labeled for | Asthma, Allergies, Crohn's disease and ulcerative colitis | Bacterial infections, Acne |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.498 per capsule 3 mg capsule | $1.96 per tablet 250 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once